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Abstract: The widespread use of combination antiretroviral therapy (cART) has led to the accelerated
aging of the HIV-infected population, and these patients continue to have a range of mild to moderate
HIV-associated neurocognitive disorders (HAND). Infection results in altered mitochondrial function.
The HIV-1 viral protein Tat significantly alters mtDNA content and enhances oxidative stress in
immune cells. Microglia are the immune cells of the central nervous system (CNS) that exhibit
a significant mitotic potential and are thus susceptible to telomere shortening. HIV disrupts the
normal interplay between microglia and neurons, thereby inducing neurodegeneration. HIV cART
contributes to the inhibition of telomerase activity and premature telomere shortening in activated
peripheral blood mononuclear cells (PBMC). However, limited information is available on the effect
of cART on telomere length (TL) in microglia. Although it is well established that telomere shortening
induces cell senescence and contributes to the development of age-related neuro-pathologies, the
effect of HIV-Tat on telomere length in human microglial cells and its potential contribution to
HAND are not well understood. It is speculated that in HAND intrinsic molecular mechanisms
that control energy production underlie microglia-mediated neuronal injury. TL, telomerase and
mtDNA expression were quantified in microglial cells using real time PCR. Cellular energetics were
measured using the Seahorse assay. The changes in mitochondrial function were examined by
Raman Spectroscopy. We have also examined TL in the PBMC obtained from HIV-1 infected rapid
progressors (RP) on cART and those who were cART naïve, and observed a significant decrease in
telomere length in RP on cART as compared to RP’s who were cART naïve. We observed a significant
decrease in telomerase activity, telomere length and mitochondrial function, and an increase in
oxidative stress in human microglial cells treated with HIV Tat. Neurocognitive impairment in HIV
disease may in part be due to accelerated neuro-pathogenesis in microglial cells, which is attributable
to increased oxidative stress and mitochondrial dysfunction.
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1. Introduction
HIV cART (combination antiretroviral therapy) has dramatically improved survival
rates of HIV infected patients, resulting in an aging HIV infected cohort, and although
viral loads remain suppressed in these patients, HIV-associated neurocognitive disorders
(HAND) remain highly prevalent and contribute to significant morbidity. Microglial
activation occurs in HIV-1 infected subjects, and uncontrolled brain inflammation plays
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a key role in neuronal injury and cognitive dysfunction during HIV infection. HIV-1
Tat is the transactivator of transcription that is essential for transcriptional regulation
and replication of the virus, and is the first protein produced after HIV infection. It
stimulates transcription of the HIV-1 genes and regulates gene expression in the host [1,2].
Tat has been implicated in the development of HIV neuro-pathogenesis and is known
to be cytotoxic and neurotoxic [3]. HIV-1 Tat protein exerts proinflammatory effects on
microglia, astrocytes and neurons that produce key pro-inflammatory cytokines, such as
tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), which ultimately lead
to neuron damage and cognitive deficits. Activated microglia also release nitric oxide (NO)
and reactive oxygen species (ROS), and contribute to mitochondrial dysfunction, further
exacerbating HAND pathogenesis [4,5]. HIV proteins can directly induce neuronal damage.
HIV-1 neuropathology results from the neurotoxic effects of the viral proteins and the
pro-inflammatory response by microglial cells. HIV-infected microglia respond vigorously
to proinflammatory signals and produce an excess of cytokines; increased IL-1β and TNF-α
levels are seen in the HAND patients. Immune-activated HIV-infected, brain-infiltrating
macrophages and resident microglia release high levels of neurotoxic cytokines, such as
TNF-α and IL-1β [6–10].
HIV cART contributes to premature telomere shortening through inhibition of the
reverse transcriptase activity of human telomerase by nucleoside reverse transcriptase
inhibitors (NRTIs), or induction of oxidative stress and mitochondrial dysfunction [11–13].
Adverse effects of cART have been attributed to the mitochondrial toxicity of NRTIs; mitochondrial dysfunction and oxidative stress are also involved in the aging processes. A
combination of HIV and cART results in the phenotype of immune senescence, which is
found in aging, however here the aging process is accelerated by oxidative stress and mitochondrial dysfunction. The interplay of these events is complex and regulation may occur
at a variety of cellular levels, involving genetic and metabolic alterations. Telomere length
is a marker of cellular replication capability, and short telomeres have been linked to aging
and age-associated diseases. HIV proteins can down-modulate expression of telomerase
activity [12,13]. Telomeric DNA loss is cumulative; when telomere length decreases until it
reaches a critical length, the cellular surveillance mechanisms are activated and cellular
proliferation ceases by permanent cell-cycle arrest or by apoptosis. Telomerase is a cellular
reverse transcriptase responsible for the de novo synthesis of telomeric DNA, and requires
reverse transcriptase to elongate the telomere. NRTIs, including zidovudine, stavudine,
tenofovir, didanosine and abacavir, inhibit telomerase effectively in vitro [11]. Telomerase
activity is also inhibited by currently recommended RTI agents, such as tenofovir and
abacavir [12,13]. NRTIs can induce oxidative stress, causing mitochondrial dysfunction.
Telomeres and telomerase activity have been characterized as biomarkers of cellular aging.
Telomeres are coated with a protein complex that consists of a group of proteins such as
telomere repeat-binding factor 1 (TRF1) and 2 (TRF2). These prevent the DNA repair machinery from recognizing and processing telomeres during the repair of double-stranded
DNA breaks.
We examined the effect of cART on TL and telomerase activity in PBMC obtained
from HIV-1 infected patients who had uncontrolled HIV infection and who were on cART
and compared them with those who were cART naïve. We observed a significant decrease
in telomere length in HIV-1 infected patients who had uncontrolled HIV infection on
cART, compared to HIV-1 infected patients who had uncontrolled HIV infection who were
cART naïve. Further, we examined changes in oxidative stress, mitochondrial cellular
energetics and alterations in expression of telomeric length, telomerase and TRF-1 in human HTHU and the HTHU/HIV microglial cells treated with a combination of tenofovir
(TFV) + emtricitabine (FTC) + dolutegravir (DTG) or cART (300 µM TFV + 50 µM FTC
+ 188 nM DTG) [14], and observed a significant decrease in telomerase activity, telomere
length and mitochondrial function, and an increase in oxidative stress in human microglial
cells treated with HIV Tat. Microglia are the immune cells of the brain; the HIV neuropathogenesis is attributed to mitochondrial dysfunction, where the mitochondria interact with
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HIV viral proteins, resulting in a significant increase in pro-inflammatory cytokines that
influence viral survival and replication. These data will help identify potential target(s) for
the regulation of microglial activation and decrease of oxidative stress, thereby limiting
microglia-associated neurotoxicity.
2. Materials and Methods
Study Design:
In vitro: Microglial cells were treated with HIV Tat (100 ng) or cART (300 µM TFV +
50 µM FTC + 188 nM DTG) for 3–24 h, followed by gene expression analysis, quantification
of mitochondrial respiration, ROS and Raman spectroscopic analysis.
In vivo: Banked PBMC samples (n = 10/group) from HIV patients who had uncontrolled HIV with detectable viral load on nucleoside analogue containing regimen
(cART = TFV, FTC, DTG) and HIV patients who had uncontrolled HIV with detectable
viral load but were treatment naïve (control group) were used in the study. Informed
consent was obtained from all subjects at enrollment for use of banked PBMC, and the
study was conducted only after approval was obtained from the institutional IRB. Samples
were de-identified and therefore no identifiable patient information was available. Subjects
in the two study groups were age and sex matched.
2.1. Cell Culture
The HTHU (transformed human µglia) and the HTHU/HIV microglial cell lines were a
generous donation from Dr. Jonathan Karn (CWRU, Cleveland, OH, USA). The transformed
immortalized human microglial cells expressed key microglial surface markers. The HTHU
cell line was generated from cryopreserved human microglia (Sciencell Cat # 1900) and
infected with vesicular stomatitis Virus G envelope Simian Virus 40 large T antigen viral
particles (VSVG SV40) containing the pBABE-puro SV40 CT construct (Addgene Plasmid
# 13970) and by spinoculation. These transformed human microglia were allowed to
expand in the presence of the selection antibiotic, puromycin (2 ug/mL) [15]. HTHU/HIV
immortalized human microglial cells bear an HIV construct as a proxy for HIV infected
primary microglia. Both HTHU and the HTHU/HIV microglial cell lines were cultured in
DMEM/F12 medium (Sigma-Aldrich, Cat No. D8437) supplemented with 5% fetal bovine
serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. Cultures were maintained
at 37 ◦ C in humidified 5% CO2 in an incubator.
2.2. Cell Viability Assay
Cell viability was measured using the CCK-8 Kit (Dojindo Molecular Technologies,
Inc., Rockville, MD, USA). The assay uses a water-soluble tetrazolium salt, WST-8, which
is reduced by dehydrogenase activity in cells to produce a yellow-color formazan dye
soluble in the tissue culture media. The amount of the formazan dye generated by the
dehydrogenase activity in cells is directly proportional to the number of living cells. HTHU
and the HTHU/HIV cells (100,000 cells) were treated with Tat (10–100 ng/mL) for 48 h,
and cell viability was measured using the CCK-8 Kit.3.
2.3. RNA Extraction
Cytoplasmic RNA was extracted by an acid guanidinium thiocyanate–phenol–
chloroform method using Trizol reagent (Invitrogen-Life Technologies, Carlsbad, CA,
USA). The amount of RNA was quantified using a Nano-Drop ND-1000 spectrophotometer
(Nano-Drop™, Wilmington, DE, USA), and isolated RNA was stored at −80 ◦ C until used.
2.4. Gene Expression Analysis Using Real Time PCR (QPCR)
Five hundred nanograms of total RNA was used for the RT reaction (25 µL total
volume) with the First-Strand cDNA Synthesis Kit (GE Healthcare, Piscataway, NJ, USA),
according to the manufacturer’s instructions. One microliter of the resultant cDNA
from the RT reaction was employed as the template in PCR reactions using well vali-
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dated primers obtained from Integrated DNA technologies (IDT). The primer sequences
used were TRF1 (forward) 50 -CCACATGATGGAGAAAATTAAGAGTTAT-30 , (reverse) 50 TGCCGCTGCCTTCATTAGA-30 ; IL-1β (forward) 50 -CTCTCACCTCTCCTACTCACTT-30
(reverse), 50 -TCAGAATGTGGGAGCGAATG-30 ; Telomerase (forward) 50 -CGTCGAGCT
GCTCAGGTCTT, (reverse) 50 -AGTGCTGTCTGATTCCAATGCTT, -30 . QPCR was performed using the Stratagene 3005P qPCR machine (Agilent, Santa Clara, CA, USA). A
standard PCR reaction was carried out using the Power® SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) and validated primers. The final primer
concentration used in the PCR was 0.1 µM. PCR conditions were as follows: 95 ◦ C for
3 min, followed by 24 cycles of 95 ◦ C for 40 s, 58 ◦ C for 30 s and 72 ◦ C for 1 min; the
final extension was at 72 ◦ C for 5 min. Ct values were obtained for the gene of interest
and the housekeeping gene beta actin. Gene expression levels were quantified using the
comparative CT method [16]. The threshold cycle (Ct) of each sample was determined, the
relative level of a transcript (2∆Ct) was calculated by obtaining ∆Ct (test Ct−GAPDH Ct),
and transcript accumulation index (TAI) was calculated as TAI = 2−∆∆CT [16].
2.5. Analysis for Telomere Length
We used the relative human telomere length quantification qPCR assay kit from
ScienCell Inc. (RHTLQ cat # 8908, ScienCell Inc., Carlsbad, CA, USA) for TL analysis.
QPCR data was analyzed using the Comparative CT method, where relative telomere
length was calculated based on the formula T/S = 2−∆∆Ct , where ∆Ct = Ct telomere-Ct
SCR or (single copy reference) primer. The relative telomere length was calculated for the
samples from patients on cART vs. patients who were cART naïve, and also the cDNA
isolated from HTHU vs. the HTHU/HIV cells.
2.6. Quantification of Mitochondrial DNA (mtDNA)
We isolated DNA from PBMC of patients on cART and patients who were cART naïve
using the Quick-DNA™ Universal Kit (Cat # D4068, Zymo Research, Irvine, CA, USA)
and quantified mtDNA using real time PCR with the following human primers: for the
target gene tRNA-Leu (UUR) (forward primer 50 -CAC CCA AGA ACA GGG TTT GT-30
and reverse primer 50 -TGG CCA TGG GTA TGT TGT TA-30 ) and nuclear β2-microglobulin
(forward primer 50 -TGC TGT CTC CAT GTT TGA TGT ATC T-30 and reverse primer 50 TCT CTG CTC CCC ACC TCT AAG T-30 ), respectively. The PCR reaction was as follows:
2 µL of template DNA (3 ng/µL isolated DNA), 2 µL of mtDNA target specific primer
pair (400 nM final concentrations each), 12.5 µL SYBR Green PCR Master Mix (Roche
Diagnostics Operations, Inc, Indianapolis IN) and 8.5 µL H2 O/well, respectively. PCR
was performed using the MX3005P (Stratagene, La Jolla, CA, USA). Samples were run in
triplicate. We obtained both mtDNA and nucDNA CT average values, and determined the
mtDNA content relative to nuclear DNA.
2.7. Mitochondrial Respiration
Microglial mitochondrial energetics was determined using the XFe24 extracellular
flux analyzer (Seahorse Bioscience, North Billerica, MA, USA). The HTHU microglial cells
were seeded in a Seahorse 24-well tissue culture plate at an optimized concentration of
50,000 cells per well. To evaluate the impact of HIV Tat (100 ng) and cART (300 µM TFV
+ 50 µM FTC + 188 nM DTG) on microglial mitochondrial respiration, these drugs were
added to the cells 24 h prior to measurement. Basal oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) were detected in the presence of physiological
concentrations of 10 mM glucose, 1 mM pyruvate and 2 mM glutamine. Next, mitochondrial ATP dependent respiration, uncoupled respiration, and non-mitochondrial
respiration were assessed after the addition of 1 µM oligomycin, 1.5 µM carbonylcyanidep-trifluoromethoxyphenylhydrazone (FCCP) and the combination of 0.5 µM each of antimycin A and rotenone, respectively. All experiments were performed using 5 wells
per treatment.

Vaccines 2021, 9, 721

5 of 17

2.8. Immunofluorescent Staining
Microglia were grown to 70% confluence in a glass petri dish and treated with HIVTat (100 ng) for 24 h. Standard immunofluorescent staining procedures were followed.
Cells were fixed for 10 min at RT using 4% formaldehyde, followed by permeabilization
with ice-cold 90% methanol. Cells were then washed in 1× phosphate buffered saline
(PBS) and treated with primary antibodies against TRF-1 (Anti-TRF1 Antibody (G-7),
cat # sc-271485) and IL1β (Anti-IL-1β Antibody (11E5) cat # sc-52012), obtained from
Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The secondary antibodies used include
fluorescence labeled Alexa Fluor® 488 Anti-mouse Secondary Antibodies, obtained from
Thermo Fisher Scientific, Grand Island, NY, USA. The expression levels of TRF-1 and
IL-1β were quantified with respect to an untreated control, based on the intensity of the
fluorescent signal analyzed using the computer image analysis ImageJ software (ImajeJ
1.38e, https://imagej.nih.gov/ij/ (accessed on 25 June 2021), 1997–2018, National Institutes
of Health, Bethesda, MA, USA). Imaging was performed with the EVOS® FL Cell Imaging
System (Life Technologies, Grand Island, NY, USA).
2.9. Reactive Oxygen Species (ROS) Measurement
ROS was quantified using the general oxidative stress indicator reagent from Invitrogen™ CM-H2DCFDA (cat # C6827). CM-H2DCFDA is a chloromethyl derivative of
H2DCFDA, useful as an indicator for reactive oxygen species in cells. CM-H2DCFDA
passively diffuses into cells, where its acetate groups are cleaved by intracellular esterases
and its thiol-reactive chloromethyl group reacts with intracellular glutathione and other
thiols, and subsequent oxidation yields a fluorescent product that can be quantified using
fluorescent microscopy imaging. HTHU cells were plated on glass-bottom petri dishes
and cells grew to 80% confluence. Cells were then treated with cART (300 µM TFV +
50 µM FTC + 188 nM DTG) for 24 h, following which the cells were washed with 1× PBS,
following which 5 µM of CM-H2DCFDA (freshly prepared in HBSS) was added, and cells
were incubated for 30 min in a dark CO2 incubator. After 30 min, the cells were washed
with PBS, and the ROS production was quantified immediately by measuring the GFP
fluorescence using EVOS® FL Cell Imaging System (Life Technologies, Grand Island, NY,
USA). Negative controls were assessed as follows: unstained cells were examined for autofluorescence in the green emission range. Measurements were obtained using excitation
sources and filters appropriate for fluorescein Ex/Em: ~492–495/517–527 nm.
2.10. Raman Spectroscopy
Raman spectra were acquired with the HORIBA XploRA PLUS Raman microspectroscope. Excitation wavelength of 532 nm was used. Cells were kept in the incubator and
removed for measurements at baseline and 24 h post treatment with cART (300 µM TFV +
50 µM FTC + 188 nM DTG). HTHU and HTHU/HIV cells were grown on quartz substrates
to minimize fluorescence. For each time point, 3 measurements of 15 accumulations of
30 s were collected. Entrance slit of 50 µm yielded an approximate spectral resolution of
4 cm−1 . Raman signal was collected by spectrometer equipped with a 1024 × 256 TE air
cooled CCD chip (pixel size 26 micron, temperature −60 ◦ C). HORIBA LabSpec6 software
(version 6.4.2) was used for data acquisition, fluorescent background removal, baseline
correction, and peak fitting.
2.11. Statistical Analysis
The data were analyzed using Graph Pad Prism 5.0 (GraphPad Software, La Jolla,
CA, USA). Results were expressed as mean ± SD; for comparisons between 2 groups, the
“t-test” was used for parametric data, and Mann–Whitney test for nonparametric data. A
p value of <0.05 was considered as a statistically significant difference.
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3.7. Effect of HIV Tat and cART on Mitochondrial Energetics
We examined the effect of HIV Tat/cART on mitochondrial stress. Microglial mitochondrial energetics was determined using the XFe24 extracellular flux analyzer (Sea-
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3.7. Effect of HIV Tat and cART on Mitochondrial Energetics
We examined the effect of HIV Tat/cART on mitochondrial stress. Microglial mitochondrial energetics was determined using the XFe24 extracellular flux analyzer (Seahorse
Bioscience, North Billerica, MA, USA). The microglial cells (HTHU) were seeded in a
Seahorse 24-well tissue culture plate at an optimized concentration of 30,000 cells per well.
To evaluate the impact of HIV Tat on microglial mitochondrial respiration, 100 ng/mL
Tat was added to the cells 24 h prior to measurement. To evaluate the impact of cART on
microglial mitochondrial respiration, cART (300 µM TFV + 50 µM FTC + 188 nM DTG)
was added to the cells 24 h prior to measurement. Basal oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) were detected in the presence of physiological concentrations of 10 mM glucose, 1 mM pyruvate and 2 mM glutamine. Next, mitochondrial ATP dependent respiration, uncoupled respiration and non-mitochondrial
respiration were assessed after the addition of 1 µM oligomycin, 1.5 µM carbonylcyanidep-trifluoromethoxyphenylhydrazone (FCCP) and the combination of 0.5 µM each of antimycin A and rotenone, respectively. All experiments were performed using five wells per
treatment. Figure 5A shows the cellular energetics profile, which provides an overview of
mitochondrial function.
As shown in Figure 5B, both 100 ng/mL Tat and cART treatment resulted in a significant reduction in mitochondrial respiration. Figure 5C shows that basal OCR was
decreased by 69% and 74% in HTHU microglial cells in response to 100 ng/mL Tat and
cART treatment, respectively. This occured due to a decreased spare respiratory capacity
(Figure 5C) in both proton leak OCR and ATP-linked OCR (Figure 5D). Mitochondrial
dysfunction occurs when oxidative modification of the respiratory chain complexes occurs,
and this event amplifies and promotes further oxidative damage. Our results show that
HIV Tat and cART impair mitochondrial respiration in microglia, as measured by maximal and spared oxygen consumption, which could lead to bioenergetic dysfunction and
production of ROS.
3.8. Effect of HIV Tat on ROS Production
Figure 6A–D shows that a significant increase in ROS production was observed in
both the HTHU cells treated with Tat (1.7-fold increase, p < 0.05) and cART (1.5-fold
increase, p < 0.05), as compared to the untreated control. The fluorescent intensity was
quantified by ImageJ (https://imagej.nih.gov/ij/ (accessed on 27 June 2021)) and expressed
in mean pixel units. It reflects increased oxidative stress that eventually contributes to
neuro-inflammation and potential neurocognitive impairment.
3.9. Effect of cART on Metabolic Changes in HTHU and HTHU/HIV Microglia Quantified by
Raman Spectroscopy
Raman spectroscopy is often used on complex biological samples to identify chemical
signatures and changes produced by alterations in the environment, such as through
cell treatment [17–26]. Inelastic Raman scattering, which occurs when there is an energy
exchange between an incident photon and a molecule, results in scattered photons of
different wavelengths than the original ones. These photons contain information revealing
the chemical structure of the sample. The main advantage of Raman spectroscopy is that
it does not require staining, fluorescent markers or any other sample processing that can
unintentionally modify the sample. Another advantage of this technique is that it is not a
specialized test, as it detects all the changes in the samples as a result of a treatment.
Raman spectroscopy was used to profile metabolic changes in HTHU and HTHU/HIV
microglia treated with cART to identify any alterations in proteins, phospholipids and nucleic acids in the cART treated microglia. For both HTHU and HTHU/HIV cells, the peak
intensity after treatment with cART was lower than at baseline, respectively (Figure 7A,B).
Our data identified reductions of the peak intensities in the spectral regions associated
with glucose (1124 cm−1 ), lipids/phospholipids (1116 cm−1 , 1098 cm−1 , 1077 cm−1 ), proteins (1120 cm−1 ), nucleic acids (1081 cm−1 ) and phenylalanine (1103 cm−1 ) upon cART
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treatment. These changes indicate a broad range of cell dysfunction. The results obtained
in this study provide insights into understanding the metabolic effects of HIV therapy.
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4. Discussion
HIV can enter the CNS during early stages of infection, and persistent CNS HIV infection and inflammation probably contribute to the development of HIV-associated neurocognitive disorders (HAND). The brain can subsequently serve as a sanctuary for ongoing HIV replication, even when systemic viral suppression has been achieved [27]. Fifty
percent of patients treated with cART have milder forms of HAND, such as asymptomatic
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4. Discussion
HIV can enter the CNS during early stages of infection, and persistent CNS HIV
infection and inflammation probably contribute to the development of HIV-associated
neurocognitive disorders (HAND). The brain can subsequently serve as a sanctuary for ongoing HIV replication, even when systemic viral suppression has been achieved [27]. Fifty
percent of patients treated with cART have milder forms of HAND, such as asymptomatic
neurocognitive impairment (ANI) and mild neurocognitive disorder (MND) [28]. HAND
generally remains stable during cART, but rarely resolves completely, therefore the real
impact of cART on HAND remains ill-defined [29,30].
Telomeres and telomerase activity have been characterized as biomarkers of cellular
aging [13]. Telomeres are coated with a protein complex consisting of a group of proteins,
such as telomere repeat-binding factor 1 (TRF1) and 2 (TRF2), which prevent the DNA
repair machinery from recognizing and processing telomeres during the repair of doublestranded DNA breaks. When telomere length becomes critically short, proliferation is
arrested, and the risk of apoptosis is increased. Critically short telomeres can cause telomere
dysfunction, which eventually induces DNA damage responses at the telomeres [31].
Proliferating cells produce telomerase, an enzyme that acts as a reverse-transcriptase,
and is responsible for catalyzing the addition of nucleotides using an RNA template [32].
Telomerase is a cellular reverse transcriptase responsible for the de novo synthesis of
telomeric DNA; it requires reverse transcriptase to elongate the telomere [33]. In HIVinfected patients, telomere shortening is caused by inhibition of human telomerase by
antiretroviral drugs, more specifically NRTIs [13,33–35]. Tenofovir (TFV) at therapeutic
concentrations is a potent inhibitor of telomerase activity, causing telomere shortening
in vitro [13,34–36]. TFV is a more potent inhibitor of telomerase than abacavir, lamivudine
or emtricitabine [13,36]. NRTIs, including zidovudine, stavudine, tenofovir, didanosine and
abacavir, inhibit telomerase effectively in vitro [12]. Telomerase activity is also inhibited by
currently recommended RTI agents, such as tenofovir and abacavir [12,13].
Despite the recognition of a role of mitochondrial toxicity in HIV and cART complications for several decades, the pathophysiology of these complications is still poorly
understood. Oxidative damage generated during oxidative phosphorylation of mitochondrial macromolecules, such as mtDNA, and alteration in mitochondrial biogenesis, may be
responsible for accelerated neuropathology in HIV patients. To our knowledge, limited
studies have explored the effects of combination antiretroviral therapy (cART), such as
nucleoside-based regimen TAF, FTC and DTG, on TL and the underlying mechanisms
such as oxidative stress and mitochondrial dysfunction which may drive these effects in
HIV-associated neurocognitive impairments in HIV-infected patients receiving these cART
regimens. Our results (Figure 1A–C) show a 40% decrease (p < 0.05) in telomere length,
a 47% increase (p < 0.05) in telomerase expression and a 37% increase (p < 0.05) in TRF-1
gene expression in infected HIV uncontrolled patients on cART, compared to infected
HIV uncontrolled patients who were cART naïve, indicating that telomere homeostasis is
regulated by telomerase and associated proteins, such as TRF1. TRF1 acts as a negative
regulator of telomere length by inhibiting telomerase activity; overexpression of TRF1 in
telomerase-positive cells results in a gradual telomere shortening, similar to observations
reported by Muñoz et al. in 2009 [37].
Neuroinflammatory response is regulated by microglia, the resident immune cells of
the CNS. Under normal circumstances the resting microglia play a pivotal role in maintaining tissue homeostasis and promoting brain development, however, upon activation
by HIV, microglia secrete high levels of proinflammatory factors and the overaccumulation of these factors causes neuronal apoptosis and subsequent cognitive impairment,
such as in HAND. Microglia are the only resident cells in the brain parenchyma that can
support productive HIV infection, and therefore are likely to be a major contributor to
neurotoxicity observed during HIV infection. Our in-vitro microglial culture experiments
showed significant decreases in TL in both HIV transfected and untransfected microglia
(Figure 2). We observed a significant decrease in the telomerase gene (Figure 3) only in
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HIV transfected microglial cells treated with HIV viral protein Tat and cART compared
to the untreated control, but no significant differences were observed in microglial cells
that were untransfected. Our data and reports from other studies suggest that HIV Tat
and cART induced changes in TL and telomerase activity that may directly contribute
to microglial cellular senescence and underlie the neurodegenerative effects observed in
HAND [38,39]. A recent study by Kronenberg, G. et al. suggested that classical microglial
activation is associated with suppression of telomere-associated genes and may underlie
microglia dysfunction [40].
Mitochondria play a critical role in the regulation of apoptosis. Therefore, mitochondrial oxidative stress contributes to neuronal apoptosis. Interpretation of studies assessing
mitochondrial complications have been limited by lack of consensus on the optimal in vivo
and ex vivo measure(s) by which to quantify mitochondrial dysfunction. Chronic HIV
infection and inflammation and/or cART drugs have adverse effects on mitochondrial function, which would contribute to long-term complications in HIV-infected persons. Patients
with HIV associated comorbidities may require additional pharmacologic interventions
that can complicate therapeutic management. Older patients with HIV are at an even
greater risk of polypharmacy-related adverse drug reactions from both ARV drugs and
other concomitantly administered medications. We examined mtDNA in DNA from PBMC
of infected HIV uncontrolled patients on cART and patients who were cART naïve. Our
results showed a 121% increase (p < 0.01) in mtDNA expression in HIV infected and HIV
uncontrolled patients on cART as compared to patients who were cART naïve (Figure 1D).
Since mtDNA encodes vital components of the OXPHOS and protein synthesis machinery,
oxidative damage-induced mtDNA mutations that impair either the assembly or the function of the respiratory chain will, in turn, cause further accumulation of ROS, which results
in a vicious cycle leading to energy depletion in the cell, and ultimately cell death. Our
results suggests that in addition to HIV viral protein, cART treatment further contributes
to mitochondrial dysfunction.
Our mitochondrial biogenesis assessment by the Seahorse assay showed that HIV Tat
and cART impairs mitochondrial respiration in microglia, as measured by maximal and
spared oxygen consumption, which could lead to bioenergetic dysfunction and production
of ROS. The role of oxidative stress in the pathophysiology of accelerated aging in HIV
is well established: reactive oxygen species (ROS) induced oxidation results in cell dysfunction and apoptosis. The production of ROS is common under oxidative stress induced
aging, and we speculate that HIV subjects may develop accelerated aging because of an
impaired mitochondrial function that induces an early senescence [41,42]. We showed
a significant increase in ROS production in HTHU microglia treated with Tat and cART,
suggesting that under non-activated conditions, microglia are likely to rely on oxidative
metabolism. However, upon stimulation, microglia may switch from oxidative metabolism
to glycolytic metabolism to support their shift in activation state. Mitochondria play a central role in the HIV neuropathogenesis process, since it is both a major ROS producer, and
a target of ROS induced dysfunction. The proximity of mtDNA to the ROS-generating electron transport chain makes mtDNA susceptible to oxidative damage. The role of metabolic
reprogramming in the regulation of innate immune responses is under investigation, and
microglial metabolism and mitochondrial dysfunction, in the context of HIV infection, is
largely understudied.
Evidence from other studies shows that activated microglial cells (BV-2) exhibit decreased oxygen consumption rates and increased lactate release, highlighting the shift from
oxidative metabolism towards glycolytic metabolism [43–45]. It is proposed that during
this shift, cells preferentially utilize glycolysis rather than oxidative phosphorylation in
an effort to preserve and generate the metabolic resources needed to meet the demands
associated with cellular proliferation and activation, while still producing a sufficient
supply of ATP [45,46]. HIV Tat has been reported to significantly reduce mitochondrial
membrane potential in mouse primary microglia, and these reductions in cellular energetics
are evidenced by decreased basal and maximal respiration, decreased ATP production and
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reduced extracellular acidification, which is a measure of glycolysis [47]. These reports and
our results confirm that Tat mediates mitochondrial dysfunction in microglia. Further, mitochondrial dysfunction triggers an inflammatory response in microglia [43,48,49], and thus
Tat-mediated mitochondrial dysfunction may fuel chronic inflammation in response to HIV
infection of microglia. Our Raman spectroscopy data suggest that both HIV Tat and cART
significantly alter proteins, phospholipids and nucleic acids in microglia, which supports
our hypothesis. Additional studies are needed to explore the impact these compounds
have on brain metabolism and subsequently cognition.
5. Conclusions
Accelerated telomere shortening contributes to genetic instability of cells, cellular
senescence, cell cycle arrest or apoptosis that may contribute to the neurodegeneration and
cognitive deficits typically observed in HAND patients. Telomere shortening occurs early
following HIV acquisition and there is a persistent decline of telomere length indicating
that telomeres are involved in the pathogenesis and clinical progression of HIV, however,
the long-term biological significance of such changes are unknown.
Overall, our data suggest that both HIV Tat and cART induce metabolic stress in
the microglia, resulting in persistent microglial activation and leading to mitochondrial
dysfunction, which could be the underlying mechanism in the neurocognitive impairment
observed in HAND patients, both in the untreated HIV patients as well as in the cART
suppressed HIV patients. It is well documented that cART regimens containing NRTIs are
potent inhibitors of telomerase activity, which we also observed in our study. Our future
investigations will examine the effect of a switch in ART regimen from NRTI to NNRTI
and its impact on telomere length in microglia and the associated biological relevance to
neuro-pathogenesis of HIV.
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